Infectious adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FAERS database
This study highlights the significant risk of iAEs in patients treated with ICIs, emphasizing the need for vigilant monitoring, particularly in older patients and those receiving combination therapies. Tailored strategies to prevent and manage infections are essential, and further research is necessary to better understand the mechanisms underlying these adverse events and to refine therapeutic approaches.
Authors
- Yan Luo (ORCID: https://orcid.org/0000-0002-5301-5092)
- Ran Zhong (ORCID: https://orcid.org/0000-0001-6840-2661)
- X. Lei
- Yana Yang (ORCID: https://orcid.org/0000-0001-9763-2845)
- Chunyu Wang (ORCID: https://orcid.org/0000-0003-3688-2116)
- Ying Wang (ORCID: https://orcid.org/0000-0002-1407-2668)
- Hu Qu
- S. Song
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Cancer Hospital (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.3389/fimmu.2025.1647944
- Citations
- 1
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- National Natural Science Foundation of China
- Chongqing Science and Technology Commission
- Fundamental Research Funds for the Central Universities